 "Natco Pharma Q3 net down 52% at Rs 14 cr")
Net profit stood at Rs 29.88 crore for the same quarter previous year.
The settlement payout, which figured as an exceptional item in the company’s profit and loss account, comes on top of a flat quarter in terms of revenues.
Also Read
Total income was almost flat at Rs 202.80 crore as compared with Rs 204.63 crore in the year ago period on account of a significant fall in revenues from formulations. Expenditure increased 1.87 per cent to Rs 160.08 from Rs 157.14 due to rise in employee costs.
At today’s meeting, the board of directors recommended an interim dividend of Rs 5 per equity share payable in March, 2015.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%